LexieCat Posted August 1, 2017 Share Posted August 1, 2017 Met with my surgeon today, who gave me the pathology report (which he is disputing tomorrow at their tumor board). The tumor was 1.5 cm, adenocarcinoma, and the issue in dispute is whether the tumor invaded the pleura--he is positive it did not, and it took the pathologists all this time to determine that, based on what THEY were seeing, it appeared that it did. Apparently all of the confusion is due to the way the original wedge resection (before they went on to perform the lobectomy) occurred. Apparently the tumor was deep within the lung, to the point where the surgeon could barely feel it. The resection basically cut through the tumor, which apparently made determination about whether it invaded the pleura difficult. The surgeon is positive, based on what he saw and felt during the surgery, that it did not invade the lining. So what it comes down to is whether the tumor itself is classed as T1a or T2a. If I understand correctly, that means the overall staging (since there were no nodes and no metastasis) is either 1a or 1b. Surgeon strongly feels that chemo would not be beneficial, but I will be meeting with oncologist on Friday--though he says he believes the oncologist is in agreement (they have discussed it). Overall, though, he was very encouraging. He said based on everything he saw, he thought recurrence was unlikely--apparently there will be CTs every six months for first two years, at least, and thereafter once a year. We didn't discuss markers or mutations--it doesn't look like that's been done (I'll ask oncologist about that on Friday), but based on what I'm reading there doesn't seem to be evidentiary support for doing any targeted therapy outside of clinical trials for this stage. Teri Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.